The path Cytokinetics has plotted for its lead heart drug will face one more potential obstacle as it approaches its PDUFA date this fall — an adcomm.
FDA told Cytokinetics it plans to convene its panel of experts to discuss the application for omecamtiv mecarbil, the biotech said Tuesday morning….
